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Background: In a subpopulation of patients with essential hypertension, therapeutic targets are not
met, despite the use of multiple types of medication. In this paper we describe our ﬁrst experience with
a novel percutaneous treatment modality using renal artery radiofrequency (RF) ablation.
Methods: Thirty patients with essential hypertension unresponsive to at least three types of antihy-
pertensive medical therapy (baseline ofﬁce systolic blood pressure P160 mmHg) were selected
between March and September 2012 and received percutaneous RF ablation. Patients were followed
up for 6 months after treatment. The primary effectiveness endpoint was change in seated ofﬁce-based
measurement of systolic blood pressure at 6 months. Another thirty patients were taken as control.
Results: A reduction of mean ofﬁce blood pressure was seen from 170/102 ± 9/5 mmHg at baseline
to 151/91 ± 8/6 mmHg at 6 months follow-up (p= 0.001). Also, we noted a signiﬁcant decrease in
plasma renin activity (3.66 ± 0.64 versus 3.37 ± 0.47 ng/mL/h; p= 0.003). No periprocedural com-
plications, adverse events or change in renal function were noted during follow-up.
Conclusion: Catheter-based renal denervation seems an attractive minimally invasive treatment
option in patients with resistant hypertension, with a low risk of serious adverse events.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.1. Introduction
Successful treatment of raised blood pressure has proven elusive
despite availability of various drugs, combination pharmaceuti-
cal products, and resources to assist patients’ adherence and
lifestyle changes. In about half of hypertensive patients, blood
pressure remains higher than accepted treatment targets despite
the broad availability of effective pharmaceutical agents.1,2
Table 1 Baseline patient characteristics.
Demographic information
Age, yrs 56 ± 6
Men,% 80
BMI, kg/m2 28.9 ± 3.3
Relevant medical history
Duration of hypertension, yrs 9.8 ± 2
Diabetes mellitus 18(60%)
CAD 12(40%)
Antihypertensive drugs
ACEI/ARB 28(93.3%)
Calcium channel blocker 28(93.3%)
B-blocker 22(73.3%)
Diuretic 30(100%)
a-blocker 2(6.7%)
Centrally acting drug 0(0%)
Values are mean ± SD or n (%).
ACEI = angiotensin-converting enzyme inhibitor; CAD= coro-
nary artery disease.
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ment of hypertension is a priority. These considerations are
especially relevant to patients with drug-resistant hypertension
and/or patients with severe intolerance to medication.
Renal sympathetic nerves contribute to development and
perpetuation of hypertension, and sympathetic outﬂow to the
kidneys is activated in patients with essential hypertension.3
Efferent sympathetic outﬂow stimulates renin release, increases
tubular sodium reabsorption, and reduces renal blood ﬂow.4
Afferent signals from the kidney modulate central sympathetic
outﬂow and thereby directly contribute to neurogenic hyper-
tension.5–7
Radical surgical methods for sympathetic denervation have
been successful in lowering blood pressure in severely hyper-
tensive patients. However, these methods were associated with
high perioperative morbidity and even mortality and also long-
term complications.4
Recently, a percutaneous, catheter-based approach using
radiofrequency energy (RF) was developed to disrupt renal
sympathetic nerves. This resulted in no severe (long-term) vas-
cular or renal injury. Importantly, catheter-based renal nerve
ablation was associated with a signiﬁcant reduction in both
systolic and diastolic blood pressure on top of maximal medi-
cal therapy, which persisted throughout 12 months follow-up
in the ﬁrst-in-man study.5
TheSymplicityHTN-2Trialwas recentlypublished,whichwas
the ﬁrst randomised controlled study using this technique of renal
denervation, conﬁrming the ﬁndings of the ﬁrst-in man study.6
Here, we report the results of the Egyptian experience
regarding this novel treatment modality.
2. Materials and methods
2.1. Study design and patients
Patients were eligible if they have an ofﬁce systolic blood pres-
sure of 160 mmHg or more, despite being compliant with at
least three antihypertensive drugs, or conﬁrmed intolerance
to medication. Blood pressure measurements were performed
in a seated position in at least two subsequent visits in both
arms. Blood pressure check was performed before intervention
and at 6 months follow-up.
Also, renal function and changes in plasma renin level were
obtained at baseline and during follow-up.
The renal artery anatomy was considered suitable in case of
a vessel diameter of P4 mm, no prior renal angioplasty/stent-
ing and no signiﬁcant stenosis or other abnormalities.
Exclusion criteria for this treatment modality were preg-
nancy, age below 18 years, patients with any known secondary
cause of hypertension and a glomerular ﬁltration rate estimated
at <45 mL/min/1.73 m2 Also, patients with type 1 diabetes,
haemodynamically signiﬁcant valvular disease or implantable
cardioverter deﬁbrillators were excluded from intervention.
Thirty patients underwent renal denervation and another
thirty patients with resistant hypertension were considered as
control.
2.2. Procedure
The baseline activated clotting time (ACT) was determined,
the renal artery was catheterized via standard femoral access,and renal angiography was then performed, after which
70 mg/kg of heparin sodium was administered. When an
ACT of 250–300 s had been achieved, a Symplicity electrode
was introduced through a renal double-curve, left internal
mammary artery, or renal short standard guiding catheter at
least 6F in diameter. The radiopaque tip of the electrode was
brought into contact with the endothelium, initially at the
most distal point of the renal trunk.
When the impedance was stable we applied RF energy for
2 min, automatically regulated to 8 W with a maximum tem-
perature of 70 C. If the impedance value recorded at the time
of RF application was too high, indicating the presence of cal-
cium, the electrode was moved to a more favorable position. If
the bifurcation was early, RF could be applied in the branches,
provided they were of adequate diameter (i.e., P4 mm).
A bilateral treatment of the renal arteries was performed
with the use of series of 2-min RF energy deliveries along each
artery, aiming at 4–6 treatment points per artery. These treat-
ment points are made with a minimum of 5 mm distance in be-
tween and with a pullback from distal to proximal in a
circumferential way. A control angiography was performed
after the procedure.
2.3. Statistical analysis
We assessed continuous variables between groups, including
the primary endpoint, with Student’s two-sample t test unless
otherwise speciﬁed. We compared categorical variables with
Fisher’s exact test. For within group paired data, a paired t test
was used unless otherwise speciﬁed. A two-sided alpha level of
0.05 was used for all superiority testing. All statistical analyses
were done using SPSS software statistical computer package
version 16.
3. Results
The baseline characteristics of the patient groups are listed in
Table 1. The mean time of the procedure (i.e. from puncture
of the femoral artery to closure) was 74 ± 9 min. Mean ﬂuo-
roscopy time was 14 ± 5 min. The ACT time achieved was
288 ± 44 s. The mean use of contrast was 208 ± 35 ml.
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formed in the left renal artery, and 5.2 ± 1 RF ablations in
the right renal artery. No patients showed endovascular dam-
age at ﬁnal angiography.
In general, there were no periprocedural (particularly access
site) complications and/or complications during follow-up. No
changes in medication were noted at 1-month follow-up. But,
there was a signiﬁcant increase in medications in the control
group after 6 months; p= 0.004 Fig. 1.
As shown in Fig. 2, after denervation, the systolic ofﬁce
blood pressure decreased from 170 ± 8 mmHg at baseline to
151 ± 8 mmHg at 6 months follow-up. This is a decrease of
19 ± 8 mmHg (p= 0.001). The diastolic blood pressure chan-
ged from 102 ± 5 mmHg at baseline to 91 ± 6 mmHg at
6 months (decrease of 11 ± 5 mmHg; p= 0.001).While in
the control group, there was no signiﬁcant decrease in blood
pressure.
No signiﬁcant change was noted in the serum creatinine le-
vel after the procedure (0.95 ± 0.18 mg/dL before compared
with 1.04 ± 0.2 mg/dL after 6 months; p= 0.234). However,
there was a statistically signiﬁcant drop in the plasma rennin
level at 6 months after denervation (from 3.66 ± 0.64 to
3.37 ± 0.47 ng/mL/h; p= 0.003) compared with the control
group (see Table 2).
4. Discussion
Our ﬁrst experience with renal sympathetic denervation, using
a percutaneous approach, conﬁrms the results of the previous
proof-of-principle and recent randomized study, showing the
safety and efﬁcacy of this new treatment modality in daily clin-
ical practice for patients with therapy resistant hypertension.5,6
The decrease of blood pressure achieved in our patient pop-
ulation is comparable with that achieved in the previous stud-Figure 1 Medication number.
Figure 2 Blood pressure folies and most likely will be clinically relevant, although current
guideline target values were not met in our patients with ex-
treme hypertension (baseline blood pressure 180/110 mmHg).7
A recent meta-analysis by Law et al. showed that irrespec-
tive of the type of medication used, the incidence of coronary
heart disease events was reduced by 22% after a systolic blood
pressure reduction of 10 mmHg or a diastolic blood pressure
reduction of 5 mmHg. Even more, the incidence of stroke
was reduced by 41%.8
Assuming that the effects of renal denervation are as effec-
tive in reducing clinical events as a pharmacological approach
for the treatment of hypertension, the observed blood pressure
reduction of 19/8 mmHg in our patients will most likely be
highly beneﬁcial. The efﬁcacy of this new treatment option
should not only be present in the short term, but particularly
during long-term follow-up.
Patients treated with this new technique approached the
6 month follow-up, and the blood pressure reductions ob-
served appear to be sustained over this period, suggesting the
absence of nerve ﬁber recovery, nerve ﬁber regrowth, or devel-
opment of counter-regulatory blood pressure- elevating
mechanisms.9
Besides efﬁcacy, safety remains an equally important issue
in a therapy for a certain disease. No adverse events were
noted in our ﬁrst patients periprocedurally and/or at follow-
up. In the ﬁrst cohort study performed in a multicentre setting,
no renal artery stenosis occurred as veriﬁed using follow-up re-
nal magnetic resonance angiogram at 6 months.5
Among all patients treated worldwide, a local dissection
without sequelae was noted during the procedure in two pa-
tients, a few access site bleedings were reported, but no
(long-term) side effects have been published up till now.6 Par-
ticularly, no change in renal function has been noted.
There is accumulating preclinical and clinical evidence com-
pelling for a primary role of renal sympathetic activation in the
pathogenesis of hypertension as described in recent review arti-
cles.10,11 A crosstalk between the central nervous system and
the kidneys is present.
Blocking sympathetic nerves leading to the kidney (‘effer-
ent’) will reverse ﬂuid and salt retention. By blocking sympa-
thetic nerves emanating from the kidney (‘afferent’), renal
denervation may also decrease the stimulation of other parts
of the sympathetic nervous system, such as the heart and blood
vessels, leading to an additional antihypertensive effect.
The earliest insight into the inﬂuence of intervention of the
sympathetic nerve activity on renal function in hypertension is
that of Claude Bernard in 1859.12 He observed that by cuttinglow up after denervation.
Table 2 shows the procedural characteristics.
No. of ablations Ablation
duration (S)
Total
RF (S)
Temp.
max. (C)
Power
avg. (W)
Mean
impedance (O)
Fluoroscopy
time (min)
Rt. Lt.
Average 5.2 ± 1 4.9 ± 1 25 ± 4 241 ± 88 39 ± 3 15 ± 3 16 ± 6 14 ± 5
Minimum 4 3 15 116 35 10 9 8
Maximum 8 6 30 389 43 18 24 23
26 H. Khamis et al.the greater splanchnic nerve, he caused an increased diuresis,
whereas electrical renal sympathetic nerve stimulation pro-
duced a reduced diuresis.
However, the surgical approach of (non-speciﬁc) renal
denervation coincided with severe side effects as observed in
studies from the 1930s using surgical denervation of the sym-
pathetic system of the thoracico–lumbar region and has there-
fore been abandoned.13,14 Using the catheter-based renal
denervation in patients as described in this paper, we may have
overcome these side effects of nonspeciﬁc denervation of the
lumbar region.15
Pathophysiological proof of concept of the denervation of
the renal artery has also been shown in a small subset of pa-
tients.16,17 Schlaich et al. demonstrated that the so called nor-
epinephrine spillover resulted in a decrease of 40–50%, which
was accompanied by halving of rennin activity and an increase
in renal plasma ﬂow. In our population, a decrease in plasma
rennin was noted.
For future therapeutic application of sympathetic denerva-
tion of the renal arteries, further research is needed to identify
groups of patients who might beneﬁt from this intervention. In
this light, searching for efﬁcacy in patients with, for instance,
chronic kidney disease, patients with heart failure, diabetes
and obesity will be interesting. Also, studies in milder forms
of essential hypertension should be the next goal of research
using this percutaneous technique. Hereby, hard endpoint
studies are warranted to prove the value of this new percutane-
ous technique in daily clinical practice.Acknowledgments
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